IPO - Hepion Pharmaceuticals, Inc.

Form Type: 424B4

Filing Date: 2025-01-23

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003271

Filing Summary: Hepion Pharmaceuticals, Inc. is conducting an offering of up to 3,661,087 shares of common stock, alongside up to 24,031,223 Pre-Funded Warrants and 27,692,310 Series A and B Warrants. The offering price for each share of common stock with accompanying warrants is set at $0.325. The Series A and B Warrants have an exercise price of $0.40 per share and will be exercisable upon stockholder approval. The Pre-Funded Warrants, priced at $0.3249 each, allow clients to purchase shares without resulting in ownership exceeding stipulated limits. The expected proceeds from this offering are approximated at $8.0 million, mainly for repaying existing Notes and for general corporate needs. The offering will terminate on January 31, 2025, unless otherwise ended earlier by Hepion. Key risks include the lack of an established market for the warrants and uncertainties surrounding compliance with Nasdaq's continued listing rules, which Hepion is attempting to address following notices of non-compliance. The company recently underwent restructuring due to funding challenges affecting its clinical development initiatives. A merger agreement previously intended to take place was terminated amid regulatory challenges, highlighting the company's ongoing strategic maneuvering to stabilize operations and seek new opportunities.

Document Link: View Document

Form Type: S-1MEF

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003130

Filing Summary: Hepion Pharmaceuticals, Inc. filed a Form S-1MEF registration statement with the U.S. Securities and Exchange Commission on January 21, 2025, to register $1,000,000 in additional shares of common stock and warrants. This filing aims to include additional Series A and Series B common stock purchase warrants totaling $1,000,000 each and provides provisions for shares issuable upon exercise of these warrants as well as pre-funded warrants. The registration is permissible under Rule 462(b) under the Securities Act of 1933, allowing for the registration of additional securities in an offering. The contents of the previously filed Registration Statement on Form S-1 (Registration No. 333-284052), including any exhibits attached, are incorporated by reference herein. The filing highlights Hepion’s classification as a smaller reporting company and emerging growth company under SEC regulations.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225002041

Filing Summary: Hepion Pharmaceuticals, Inc. filed Amendment No. 1 to its registration statement (Form S-1) on January 14, 2025, with the SEC to propose an initial public offering (IPO) of up to 14,285,714 shares of common stock, along with pre-funded warrants and series A and B warrants, all targeted for public sale. This offering is a reasonable best efforts arrangement with an assumed combined public offering price of $0.56 per share based on recent market conditions. The company is working to regain compliance with Nasdaq listing requirements due to recent valuation challenges and uncertainties in its stock price. The document also discusses a strategic restructuring plan initiated to cut operating costs and maximize stockholder value, alongside recent developments concerning a terminated merger agreement with Pharma Two B Ltd. Furthermore, Hepion's ability to maintain its listing on Nasdaq is under scrutiny, with the company recently submitting a compliance plan to avoid delisting.

Document Link: View Document